US Edition
News from Independent-Messenger
If you want to know if Independent-Messenger is credible or reliable, look no further. We rank Independent-Messenger as Unknown factuality. Find out more about our methodology here.
Information about Independent-Messenger
Where is Independent-Messenger located?Emporia, United StatesIndependent-Messenger's WebsiteIndependent-Messenger's TwitterMedia Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Independent-Messenger News
North Carolina · North Carolina(Family Features) As the cost of living continues to rise, many Americans are being forced to make difficult financial decisions. Skipping medications might seem like a quick way to save money, but this can lead to serious health risks and…See the Story
Cutting Medication Costs Without Cutting Corners
63% Center coverage: 41 sources
Artificial Intelligence · United KingdomNational Grid and Emerald AI are partnering to show how AI data centres can support a smarter, more flexible grid.A UK-first live trial is planned for late 2025 on a grid connected data centre using Emerald AI's platform and cutting-edge…See the Story
National Grid and Emerald AI Announce Strategic Partnership to Demonstrate AI Power Flexibility in the UK
54% Center coverage: 26 sources
Hong Kong City · Hong KongHONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225). The trial will evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4…See the Story
Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma
48% Center coverage: 25 sources
